Adaptimmune Ther ADR (ADAP) Stock Price, Quote & News

Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the t...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 12 3543 0000

Website: www.adaptimmune.com

Address:

60 Jubilee Avenue, Milton Park, Abingdon, United Kingdom

321rip Aug. 2 at 9:44 PM

$ADAP TH. posted LO, Fri. s/o remaining negative Nancy's, plus HI HI HI LO on higher vol.

1 · Reply

Ernesto62 Aug. 2 at 6:13 PM

$ADAP really?

0 · Reply

Processresult Aug. 2 at 5:43 PM

$ADAP "UNWIND" JUST LIKE "GRITSTONE"

0 · Reply

Ernesto62 Aug. 2 at 6:46 AM

$ADAP Going Concern Our 2024 Annual Report on Form 10-K, which the Company filed on March 24, 2025, disclosed that there is substantial doubt about our ability to continue as a going concern. We are continuing to implement cost reduction measures and explore the strategic options outlined above.

1 · Reply

Ernesto62 Aug. 2 at 6:43 AM

$ADAP pipeline useless after cell sales

1 · Reply

Ernesto62 Aug. 2 at 6:20 AM

$ADAP no

0 · Reply

super35362 Aug. 2 at 4:44 AM

Here are four stocks to watch on Monday. Which one do you think will perform well, and why? $ATCH $AIRE $GIBO $ADAP

0 · Reply

Bombo523914 Aug. 1 at 11:48 PM

$ADAP is $1.00 doable for this?

1 · Reply

leonardi Aug. 1 at 11:03 PM

$ADAP i wish adrian had shown any sincere interest to return anything to shareholders like he did for his personal buddies at Hercules even returning money before due. Not only that holders of this trash had to pay ADR fees all these years. I am surprised not single law firm has shown interest here usually ambulance chasers show up right away.

2 · Reply

locallab Aug. 1 at 10:42 PM

$ADAP seriously? Can't joke about Mike pics on here?

1 · Reply

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

May 13, 2025, 1:59 PM EDT - 2 months ago

Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 2 months ago

Adaptimmune Reports Q1 Financial Results and Provides Business Update

May 7, 2025, 12:00 PM EDT - 3 months ago

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Mar 20, 2025, 12:10 PM EDT - 4 months ago

Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:00 AM EDT - 4 months ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Mar 12, 2025, 4:54 PM EDT - 5 months ago

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Jan 30, 2025, 4:00 PM EST - 6 months ago

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Jan 13, 2025, 8:00 AM EST - 7 months ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Dec 19, 2024, 7:30 AM EST - 8 months ago

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Dec 2, 2024, 4:00 PM EST - 8 months ago

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Nov 13, 2024, 7:48 PM EST - 9 months ago

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:05 PM EST - 9 months ago

Adaptimmune Reports Q3 2024 Financial and Business Updates

Nov 13, 2024, 9:00 AM EST - 9 months ago

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Nov 5, 2024, 9:19 AM EST - 9 months ago

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Oct 31, 2024, 5:20 PM EDT - 9 months ago

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Adaptimmune to Participate in Two Bank Conferences this September

Aug 12, 2024, 11:42 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Reports Q2 2024 Financial and Business Updates

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Aug 2, 2024, 9:20 AM EDT - 1 year ago

US FDA approves Adaptimmune's gene therapy for rare type of cancer

Aug 1, 2024, 8:20 PM EDT - 1 year ago

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Jul 3, 2024, 9:54 AM EDT - 1 year ago

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jun 17, 2024, 2:05 PM EDT - 1 year ago

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Jun 3, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

May 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

GLPG

May 30, 2024, 4:01 PM EDT - 1 year ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

GLPG

May 15, 2024, 10:07 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

May 15, 2024, 7:30 AM EDT - 1 year ago

Adaptimmune Reports Q1 2024 Financial and Business Updates

May 15, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

HTGC

May 1, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Apr 26, 2024, 11:00 AM EDT - 1 year ago

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Mar 27, 2024, 7:30 PM EDT - 1 year ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Mar 6, 2024, 9:29 AM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:00 AM EST - 1 year ago

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Feb 27, 2024, 8:00 AM EST - 1 year ago

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Feb 21, 2024, 4:00 PM EST - 1 year ago

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Jan 31, 2024, 4:44 PM EST - 1 year ago

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Jan 4, 2024, 7:37 AM EST - 1 year ago

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Dec 6, 2023, 7:00 AM EST - 1 year ago

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Nov 29, 2023, 8:00 AM EST - 1 year ago

Adaptimmune Receives Transfer of IND for Lete-cel Program

Nov 8, 2023, 11:45 AM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 7:30 AM EST - 1 year ago

Adaptimmune Reports Third Quarter Financial Results and Business Update

Nov 8, 2023, 7:05 AM EST - 1 year ago

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Oct 25, 2023, 8:06 AM EDT - 1 year ago

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Oct 23, 2023, 4:15 AM EDT - 1 year ago

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

Sep 12, 2023, 8:48 AM EDT - 2 years ago

Adaptimmune: Spinning Sarcoma Into Gold

321rip Aug. 2 at 9:44 PM

$ADAP TH. posted LO, Fri. s/o remaining negative Nancy's, plus HI HI HI LO on higher vol.

1 · Reply

Ernesto62 Aug. 2 at 6:13 PM

$ADAP really?

0 · Reply

Processresult Aug. 2 at 5:43 PM

$ADAP "UNWIND" JUST LIKE "GRITSTONE"

0 · Reply

Ernesto62 Aug. 2 at 6:46 AM

1 · Reply

Ernesto62 Aug. 2 at 6:43 AM

$ADAP pipeline useless after cell sales

1 · Reply

Ernesto62 Aug. 2 at 6:20 AM

$ADAP no

0 · Reply

super35362 Aug. 2 at 4:44 AM

Here are four stocks to watch on Monday. Which one do you think will perform well, and why? $ATCH $AIRE $GIBO $ADAP

0 · Reply

Bombo523914 Aug. 1 at 11:48 PM

$ADAP is $1.00 doable for this?

1 · Reply

leonardi Aug. 1 at 11:03 PM

2 · Reply

locallab Aug. 1 at 10:42 PM

$ADAP seriously? Can't joke about Mike pics on here?

1 · Reply

Shuqishuqi Aug. 1 at 10:02 PM

$RAYA why can't $ADAP do the same

1 · Reply

aladinironman Aug. 1 at 9:48 PM

$ADAP something brewing here ! will see 0.15+ sometimes next week !

1 · Reply

Q12021Dreaming Aug. 1 at 8:59 PM

$ADAP Receiving 55 Million and another 30 Million and this tanks? I'm in!

0 · Reply

Q12021Dreaming Aug. 1 at 8:58 PM

$ADAP Receiving 55 Million in cash and another 30 million later and this tanks? I'm in!

0 · Reply

JustEk33 Aug. 1 at 8:23 PM

$ADAP no…that title belongs to @dhovekamp42

2 · Reply

keypatience Aug. 1 at 8:21 PM

$IOVA $XBI $LIVN $URGN $ADAP This dude is the biggest dummy on Stocktwits.

3 · Reply

Mixtrix Aug. 1 at 7:53 PM

$ADAP you are foolish to not take this chance

1 · Reply

taneraydar Aug. 1 at 7:34 PM

$ADAP Holding 565k shares still… hopeless for now. I was excited earlier today but it seems we will hanging around these levels a few weeks

1 · Reply

LarryFin Aug. 1 at 7:28 PM

$ADAP So i sold my short Shares. I had earn enough money. Sorry, bagholders, this Stock is dead and absolutely trash. Nice Weekend 🤩

0 · Reply

mrdoing Aug. 1 at 7:14 PM

$ADAP The short is over, it's strong, not 5000 dollars but 50000 dollars. Beware of stop losses.

0 · Reply

Joe__321 Aug. 1 at 7:13 PM

$ADAP ADAP deserves some love! right now. to all who believe in this science and I mean really in this science.

1 · Reply

mrdoing Aug. 1 at 6:57 PM

$ADAP the absolute minimum has been made, all short positions have been closed. Now it accumulates and eye that breaks the 0.115 goes to 0.70. eye 👁 MONE

0 · Reply

Market Cap	21.18M
Revenue (ttm)	178.03M
Net Income (ttm)	-70.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.77%
Debt to Equity Ratio	-0.68

Volume	84,262,898
Avg Vol	7,712,116
Day's Range	N/A - N/A
Shares Out	265.05M
Stochastic %K	2%
Beta	2.18
Analysts	Hold
Price Target	$1.09